147489-30-3

Basic information

• Product Name: 1-benzyl 2-tert-butyl (2S)-5-oxopiperidine-1,2-dicarboxylate
• Synonyms: 1-benzyl 2-tert-butyl (2S)-5-oxopiperidine-1,2-dicarboxylate;tert Butyl 1-Cbz-(2S)-5-Oxopiperidine-2-Carboxylate;1-benzyl 2-(tert-butyl) (S)-5-oxopiperidine-1,2-dicarboxylate
• CAS NO: 147489-30-3
• Molecular Formula: C₁₈H₂₃NO₅
• Molecular Weight: 333.37892
• Mol File: 147489-30-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-benzyl 2-tert-butyl (2S)-5-oxopiperidine-1,2-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl 2-tert-butyl (2S)-5-oxopiperidine-1,2-dicarboxylate(147489-30-3)
• EPA Substance Registry System: 1-benzyl 2-tert-butyl (2S)-5-oxopiperidine-1,2-dicarboxylate(147489-30-3)

Safety Data

• Hazardous Substances Data: 147489-30-3(Hazardous Substances Data)

Usage

Chemical structure

A complex structure that includes a benzyl group, a tert-butyl group, and a piperidine ring.

Ester derivative

It is an ester derivative of piperidine-1,2-dicarboxylic acid.

Chiral compound

It is a chiral compound with a stereochemistry at the 2-position of the piperidine ring.

Stereochemistry

The stereochemistry is (2S), indicating the configuration of the chiral center at the 2-position.

Potential pharmacological properties

Due to its structural features, it may have potential pharmacological properties.

Medicinal chemistry research

It could be used in medicinal chemistry research for the development of new drugs.

Further studies needed

Further studies on its physical and chemical properties, as well as its potential biological activities, are needed to fully understand its potential applications.

Molecular weight

Approximately 369.46 g/mol (calculated from the molecular formula)

Appearance

It is likely a solid, based on the presence of multiple functional groups and the size of the molecule.

Upstream product

• 81470-51-1 tert-butyl N-benzyloxycarbonyl-L-pyroglutamate 
• 32159-21-0 Cbz-L-pGlu-OH 
• 623-73-4 diazoacetic acid ethyl ester 
• 147489-27-8 (2S)-4-oxo-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid tert-butyl ester 

Downstream Products

• 1192651-49-2 (1R,2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide 
• 1383814-64-9 (2S,5R)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide 
• 1174020-25-7 (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid 
• 1383814-57-0 (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid cyclohexylamine salt 
• 1383814-55-8 (2S,5R)-tert-butyl 5-(benzyloxyamino)piperidine-2-carboxylate 
• 1383814-54-7 (2S,5R)-tert-butyl 5-(benzyloxyamino)-1-(2,2,2-trifluoroacetyl)piperidine-2-carboxylate 
• 1383814-56-9 (2S,5R)-tert-butyl 6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate 
• 169825-97-2 N-benzyloxycarbonyl-(2S,5S)-5-hydroxypipecolic acid tert-butyl ester 
• 154307-84-3 (2S,5S)-5-hydroxypiperidine-2-carboxylic acid hydrogen chloride 
• 1452466-57-7 (2S,5R)-6-(benzyloxy)-N-methoxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide 
• 1452467-32-1 (2S,5R)-6-(benzyloxy)-7-oxo-N’-propanoyl-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide 
• 1426572-71-5 (2S,5R)-N’-acetyl-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide 
• 1383814-58-1 (2S,5R)-6-benzyloxy-7-oxo-1,6-diazabicyclo[3.2.1]octan-2-carboxylic acid methyl ester 
• 1416134-73-0 (2S,5R)-5-((benzyloxy)amino)piperidine-2-carboxylate methyl ester 

Relevant articles and documents

NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME

The currently available β-lactamase inhibitors are insufficient to inhibit the incessantly increasing β-lactamase, and novel β-lactamase inhibitors has been required today for the difficult treatment for bacterial infectious diseases caused by resistant bacteria which produce class C β-lactamase, extended-spectrum β-lactamase (ESBL) belonging to class A and D, or class A KPC-2 decomposing even carbapenem as a last resort for β-lactam antibiotic. A compound represented by the the formula (I), preparation process of the same, β-lactamase inhibitors and method for treating bacterial infectious diseases are provided.

OPTICALLY ACTIVE DIAZABICYCLOOCTANE DERIVATIVES AND PROCESS FOR PREPARING THE SAME

Provided are an optically active diazabicyclooctane derivative defined by formula (F) below, which is useful as a pharmaceutical intermediate for beta-lactamase inhibitor, and a process for preparing the same. In formula (F) above, R1 represents CO2R, CO2M, or CONH2, wherein R represents a methyl group, a tert-butyl group, an allyl group, a benzyl group, or a 2,5-dioxopyrrolidin-1-yl group, and M represents a hydrogen atom, an inorganic cation, or an organic cation; and R2 represents a benzyl group or an allyl group.

Diastereoselective synthesis of (2S,5S)- and (2S,5R)-N-benzyloxycarbonyl-5-hydroxypipecolic acids from trans-4-hydroxy-l-proline

An efficient diastereoselective synthesis of cis- and trans-5-hydroxy-(2S)-N-benzyloxycarbonyl pipecolic acids, starting from trans-4-hydroxy-l-proline is described. The key synthetic strategies involve the regioisomeric ring expansion of keto ester 8 and diastereoselective reduction of ketone 11 in high selectivity and yield.